No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation.

about

No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation.

Item

http://www.wikidata.org/entity/Q47572547

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

No indication of increased inf ...... eic stem cell transplantation.

@en

No indication of increased inf ...... eic stem cell transplantation.

@nl

type

Item

label

No indication of increased inf ...... eic stem cell transplantation.

@en

No indication of increased inf ...... eic stem cell transplantation.

@nl

prefLabel

No indication of increased inf ...... eic stem cell transplantation.

@en

No indication of increased inf ...... eic stem cell transplantation.

@nl

P1476

No indication of increased inf ...... neic stem cell transplantation

@en

P2093

Christian Schmidt

http://www.w3.org/2001/XMLSchema#string

Daniel Pink

http://www.w3.org/2001/XMLSchema#string

Laila Schneidewind

http://www.w3.org/2001/XMLSchema#string

Meike Schulze

http://www.w3.org/2001/XMLSchema#string

Thomas Thiele

http://www.w3.org/2001/XMLSchema#string

William Krüger

http://www.w3.org/2001/XMLSchema#string

P2860

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.

CAMPATH: from concept to clinic.

Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.

Retrospective analysis of fluoroquinolone prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation.

Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation.

Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival.

Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation.

Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies.

P31

scholarly article

P356

10.1111/TID.12822

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Neumann

P577

2017-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29178248

http://www.w3.org/2001/XMLSchema#string